What is MOTS-c?
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a short peptide of 16 amino acids encoded not by nuclear DNA but by the mitochondrial genome. That origin makes it unusual: most known peptides are products of nuclear gene expression. MOTS-c was identified in 2015 by researchers at the USC Davis School of Gerontology who found that it regulated metabolic homeostasis in preclinical models.
The research framing for MOTS-c positions it as a mitokine — a mitochondria-derived signaling peptide that communicates metabolic stress information to other tissues. Circulating MOTS-c levels in humans decline with age, which has generated interest in whether exogenous supplementation could influence aging-associated metabolic changes.
What does “MOTS-c protocol” mean in research?
When researchers describe a MOTS-c protocol, they are referring to the dose, route, and timing parameters used in a specific animal study. The phrase does not yet refer to a validated human therapeutic regimen, because no large-scale controlled human trials have been completed and published.
Understanding this distinction is important: protocol parameters from rodent studies are not interchangeable with human use guidelines. Species differences in pharmacokinetics, receptor distribution, and metabolic rate make direct dose translation unreliable.
Every published MOTS-c “protocol” is an animal-study dose — not a validated human regimen, and not a license to self-experiment.
What dose ranges have been used in MOTS-c preclinical studies?
Preclinical MOTS-c protocols have varied considerably across studies. The original 2015 Cell Metabolism paper by Lee et al. used intraperitoneal doses of 0.5 mg/kg and 15 mg/kg in mice. The 2021 Nature Communications study by Reynolds et al. used 15 mg/kg administered subcutaneously in aged mice over several weeks.
Several parameters are worth noting from the published literature:
- Route: Most studies have used intraperitoneal (IP) or subcutaneous (SC) injection. IP is a standard rodent research route that does not translate to standard human administration.
- Frequency: Daily and every-other-day schedules have both been used across different studies, typically over 4- to 12-week periods. No comparative frequency data in humans exists.
- Duration: Protocols have ranged from single-injection pharmacokinetic studies to multi-week repeated dosing. Long-term repeated dosing in humans has not been studied.
- Weight-based scaling: Rodent doses reported in mg/kg do not translate linearly to human doses. The FDA’s body surface area conversion method gives a rough conversion, but this is a starting estimate for study design, not a clinical recommendation.
What has MOTS-c research explored?
The preclinical literature on MOTS-c protocol effects has concentrated in several areas:
Metabolic homeostasis
The original discovery paper demonstrated that MOTS-c administration in high-fat-diet mice supported metabolic homeostasis, including effects on glucose regulation markers and body composition. The proposed mechanism involves MOTS-c targeting the folate cycle and de novo purine biosynthesis, leading to AMPK pathway activation. These findings have generated scientific interest but require human replication.
Physical performance and muscle homeostasis
The 2021 Reynolds et al. study found that MOTS-c administration in aged mice — animals that had shown age-related physical decline — supported muscle homeostasis and physical capacity markers. Circulating MOTS-c was also found to increase with exercise in both mice and humans in that study, positioning MOTS-c as an exercise-responsive mitokine. Whether exogenous MOTS-c replicates or augments this exercise-induced response in humans is not established.
Age-related decline
Circulating MOTS-c levels decline measurably with age in humans. This observation has driven the hypothesis that MOTS-c replacement could influence aging-related metabolic and physical changes. The hypothesis is biologically plausible, but causal evidence in humans is absent. Observational correlation between lower MOTS-c and aging does not establish that supplementing MOTS-c reverses or slows those processes.
Does MOTS-c timing relative to exercise matter?
Because MOTS-c is endogenously released during exercise, some researchers have explored whether timing MOTS-c administration relative to physical activity might be relevant. In animal protocols, administration has typically been independent of exercise timing. Whether exercise-synchronized dosing matters in humans — and in what direction — is speculative.
The exercise-MOTS-c relationship is one of the more intriguing aspects of the research. But it is premature to conclude that taking MOTS-c before or after exercise amplifies exercise benefit. The data does not support that claim in humans.
What is MOTS-c’s regulatory status and availability?
MOTS-c is not currently on the FDA’s Category 1 list of bulk drug substances that licensed 503A compounding pharmacies may use. This means access through legitimate U.S. licensed compounding pharmacies is currently restricted. Obtaining MOTS-c from gray-market or overseas sources carries significant risks related to purity, sterility, concentration accuracy, and contamination. PepScribe strongly advises against obtaining any peptide from unregulated sources.
The regulatory landscape for peptides has been evolving. Several compounds removed from Category 2 compounding restrictions in recent regulatory actions remain in a transitional status pending formal Federal Register publication. Monitoring updates from FDA.gov and consulting a licensed clinician is the appropriate way to track what is currently accessible.
What alternatives are currently available?
Patients interested in mitochondrial health and longevity support may find that other clinician-supervised options are currently accessible through legitimate U.S. compounding channels. NAD+ (nicotinamide adenine dinucleotide) is a well-studied cofactor in mitochondrial energy metabolism available through licensed 503A pharmacies with clinician oversight.
You can read about NAD+ therapy and how it supports mitochondrial function as a starting point. A clinician consultation through PepScribe’s Longevity & Cellular Health program can help identify which currently available therapies align with your metabolic and performance goals.
Frequently asked questions
What is the MOTS-c protocol used in research?
Preclinical studies have used MOTS-c at doses ranging from 0.5 mg/kg to 15 mg/kg via intraperitoneal or subcutaneous injection. No standardized human dosing protocol has been established through controlled clinical trials.
How often is MOTS-c administered in animal studies?
Research in rodent models has used daily or every-other-day subcutaneous injection schedules, often over 4–12 week periods. These schedules have not been validated in human clinical trials.
Is MOTS-c available from compounding pharmacies?
MOTS-c is not on the FDA Category 1 list of bulk drug substances that licensed 503A compounding pharmacies may use. Access through legitimate U.S. compounding channels is currently restricted. A clinician consultation can clarify which mitochondrial-support options are currently available.
What does MOTS-c research show about exercise?
Preclinical data suggests MOTS-c is secreted during exercise and may play a role in mitochondrial biogenesis and metabolic homeostasis. Human data is limited and no causal exercise-benefit claims for supplemental MOTS-c in humans are currently supported.
Is MOTS-c the same as a steroid or HGH?
No. MOTS-c is a mitochondrial-derived peptide — a short chain of amino acids encoded in mitochondrial DNA. It has a distinct mechanism of action from anabolic steroids and is unrelated to human growth hormone (HGH).
Where can I learn about peptide programs that are currently available?
PepScribe's Longevity & Cellular Health program covers clinician-supervised therapies in the cellular optimization space. A free intake consultation will help determine what is available and appropriate for your goals.